^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Glioma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    GLIOMA: Useful in Certain Circumstances…Selumetinib…(for PA with BRAF fusion or BRAF V600E activating mutation)…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

    Excerpt:
    ...- Non-neurofibromatosis type 1 (non-NF1), non-tuberous sclerosis complex (non-TSC) low-grade glioma (LGG) without a BRAFV600E or IDH1 mutation...
    Trial ID:
    NCT04576117
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Excerpt:
    ...Plasma drug concentrations and pharmacokinetic parameters (Phase I)`Stratum-specific progression-free survival distribution (PFS) (phase II)`Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)`Progression-free survival (retreatment study)...
    Trial ID:
    NCT01089101
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

    Excerpt:
    ...- Patients must have non-neurofibromatosis type 1 (non-NF1) low-grade glioma (LGG) without a BRAFV600E mutation as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1 (NCT02402244) and that has...
    Trial ID:
    NCT04166409
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    AZD6244 in Children With Low-Grade Gliomas

    Excerpt:
    ...- Stratum 1: Patients with progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAF (V600E) mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively. ...
    Trial ID:
    NCT01386450
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.

    Excerpt:
    Selumetinib was effective in treating children with recurrent/refractory LGG, including those with NF-1 associated LGG and PA harboring BRAF V600e mutation or BRAF-KIAA 1549 fusion.
    DOI:
    10.1200/JCO.2017.35.15_suppl.10504
    Trial ID:
    NCT01089101